Seeking Alpha

ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase...

ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase III trial for Pimavanserin. "Home run for them," is Jason Napodano's quick take after looking over the data. Of particular interest, he says, is the testing showed no negative impact on motor function, unlike clozapine or quetiapine.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|